# A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression

> **NCT00250653** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 365 (actual)

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** Saredutant succinate (SR48968C)

## Key facts

- **NCT ID:** NCT00250653
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2012-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250653, "A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00250653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*